On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

TCR-α/β and CD19 depleted stem cell grafts from haploidentical donors for allogeneic transplantation in patients with relapsed lymphoma ... refractory B-cell acute lymphoblastic leukemia ...

Citation Format: Alessandra Perini, Marti Brucoli, Sophie Acton, Luigi Ombrato. Understanding myeloid and lymphoid cell heterogeneity following radiotherapy and its impact on metastasis development in ...

Boston – Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia ... and ...

Lymphomas, lymphocytic leukemias, and myeloma are from the lymphoid line, while acute and chronic myelogenous leukemia, myelodysplastic syndromes and myeloproliferative diseases are myeloid in origin.

According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 70% phase transition ... T-cell acute lymphocytic leukemia and Hodgkin lymphoma. Vincerx Pharma (Vincera) is a ...

Actress Susan Sullivan, 82, who announced she was “cancer-free” from non-small cell lung cancer (the most common type of lung cancer) last year, is now battling lymphoma. She hasn’t specified what ...

Acute myeloid leukemia (AML) is an aggressive hematological malignancy; it is the most common acute leukemia in adults. AML prognosis is often poor, and relapse often occurs after initial remission.

Background: Leukemia is the 11 th most prevalent type of cancer worldwide, with acute myeloid leukemia (AML) being the most frequent malignant blood malignancy in adults. Microscopic blood tests are ...